Kornimate/medical-research-clean huggingface dataset:
famciclovir in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this is a proof-of-concept study in 30 patients with established relapsing remitting multiple sclerosis (rrms). imp is famciclovir. it is a phase ii type a open label study. each individuals participation in the study will last 36 weeks and will be divided into three phases: pre-treatment (12 weeks), treatment with famciclovir (12 weeks), and post-treatment (12 weeks). during the first 12 week phase patients will remain on their usual treatment alone; this will be followed by three months of co-treatment with famciclovir and then followed by a final three months post-famciclovir treatment where participants will continue to take their usual treatment for rrms. the primary aim is to explore the effect of famciclovir (500mg bd) on epstein-barr virus (ebv) shedding in the saliva of patients with ms


Eligibility criteria:
inclusion criteria: * diagnosed with ms * males and females aged over 18 * taking natalizumab (tysabri) for the treatment of ms, * be able to provide informed consent to take part in this study. * female patients of childbearing potential (defined in section 13.4) must be willing to follow protocol contraceptive requirements. exclusion criteria: * taking ms disease modifying treatment other than natalizumab (tysabri) * on no treatment for ms * taking additional immunomodulatory agents (either for ms treatment or other reasons) * has received a course of high dose oral or intravenous steroids within 3 months of study entry. the use of low dose (total daily dose \<10mg) and/or the use of topical steroids will not act as an exclusion criteria. * taking antiviral or antiretroviral medication for any reason * known allergy to penciclovir, acyclovir, valaciclovir or famciclovir * taking probenecid * significant renal (ckd 3 or 4) and/or liver (alt\>3x uln) impairment * pregnant, or unwilling to take measures to prevent pregnancy * breastfeeding
intermittent low energy diet in ckd: mix up feasibility study

Conditions: Chronic Kidney Diseases; Obesity

Summary: this study proposes to investigate the acceptability and efficacy of intermittent vled (5:2 diet) plus exercise, compared with the investigator's established weight management programme (wmp), in obese patients with ckd, using feasibility study methodology. patients will be invited to participate in the parallel arm, single blinded, randomised controlled feasibility study, and randomly allocated to 1 of 2 treatments for 6 months. the experimental arm involves an intermittent modified fasting regimen consisting of vled (600 kcal/day) on 2 consecutive days, and 5 days each week on a modified diet to maintain an overall energy deficit of 600 kcal/day across the week (5:2 diet). the control arm will be the standard renal wmp with a continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day. the feasibility outcomes are: recruitment rate \>50%; intervention retention rate at 6 months \>60%; dietary intervention compliance; and weight loss. secondary outcomes include safety, body composition, proteinuria, lipids, blood pressure, and eating desire. measurements will be made at baseline, midpoint, and twice at endpoint.


Eligibility criteria:
inclusion criteria: * aged 18-75 years * kdigo defined ckd (all categories) * bmi ≥30kg/m2 * able to provide written informed consent in english exclusion criteria: * pregnant or breastfeeding women * conservatively managed ckd stage 5 * palliative or active treatment for cancer * unstable chronic liver disease * type 1 diabetes and type 2 diabetes controlled with anti-hyperglycaemic medication * previous bariatric surgery * unable to provide written informed consent * significant psychiatric disorder or uncontrolled depression * participated in a weight management drug trial in the previous 3 months * uncontrolled epilepsy * alcohol or substance abuse

Keywords: intermittent fasting weight loss
descriptive study of pathogens involved in summer diarrhea in children leading to pediatric emergency room visits (pe-dia)

Conditions: Diarrhea, Infantile

Summary: acute diarrhea in children is a public health problem. it is estimated that children under 3 years are subject to 1 or 2 episodes of diarrhea per year in europe. these diarrheal episodes are frequent, expensive and responsible for many consultations and hospitalizations in developed countries. the origin of diarrhea in children is viral in about 70% of cases. the diagnosis of a viral infection is often considered without microbiological evidence. however, microbiological evidence is recommended for certain categories of patients. the involvement of bacteria or parasites in the child's diarrhea does not seem negligible. the main objective of this study is to estimate the prevalence of infectious diarrhea among summer diarrhea in children leading to pediatric emergency room visits. secondarily, we will describe the pathogens responsible for childhood diarrhea during the summer period, describe common factors that can serve as guidance on the etiology of diarrhea, and describe common factors that can be used as tools. preventive to the transmission of these pathogens.

after obtaining consent from the holders of parental authority, a stool collection will be requested from all pediatric emergency patients presenting as a reason for "diarrhea" consultations between june 1 and september 30, 2020. it will be given by the nurse organizing the reception, a medical information questionnaire and a stool collection container for those accompanying a child with diarrhea. if the child presents stool during the waiting period or during the medical consultation, these will be collected and sent to the medical biology laboratory of the university hospital for a broad analysis (virological, bacteriological and parasitological). the doctor in charge of the patient will complete a pre-established clinical information sheet. in the laboratory, the stool will be taken care of and a dna extract will be made and preserved. the search for pathogens will be carried out by molecular biology, by series, non-prospectively. the results will only be transmitted at a distance and will not be communicated to families. therapeutic management of children included in the study will be identical to the usual practice. microbiological analysis will not delay, prolong or disrupt the treatment of the acute episod of diarrhea.

Eligibility criteria:
inclusion criteria: * children aged from 0 to 16 years with diarrhea * pediatric emergency at the university hospital of clermont-ferrand consultation * between june and september 2020 exclusion criteria: * consent not felt by the child or the person with parental authority * no stool removal

Keywords: microbiologic diagnosis summer diarrhea pediatric population
physiotherapy assessment based on the icf model in the lesch-nyhan syndrome: case report

Conditions: Lesch-Nyhan Syndrome

Summary: lesch-nyhan syndrome (lns) is a genetic disorder that results in a deficit in the hypoxanthine-guanine phosphoribosyltransferase (hprt) enzyme, which affects purine metabolism. it is a genetic disorder that is carried by an x-linked recessive gene. lns has 3 typical symptoms. these are increased uric acid, neurological symptoms and behavioral disorders. dystonia is often seen among its neurological manifestations. signs of primidal and extraprimidal system can be seen. it is very important to create the syndrome-specific physiotherapy program. in order to achieve this, evaluations based on the international classification of functioning, disability and health (icf) model are valuable in terms of showing the right way in the management of the disease.

lesch-nyhan syndrome (lns) is a genetic disorder that results in a deficit in the hypoxanthine-guanine phosphoribosyltransferase (hprt) enzyme, which affects purine metabolism. it was described by lesch and nyhan in 1960. it is a genetic disorder that is carried by an x-linked recessive gene and is therefore predominantly seen in males. lns has 3 typical symptoms. these are increased uric acid, neurological symptoms and behavioral disorders. self-harming behavior begins to appear from the age of 2. dystonia is often seen among its neurological manifestations. signs of primidal and extraprimidal system can be seen. as developments in treatment methods continue in individuals with lns, the expected life expectancy of these individuals is prolonged. however, these individuals require physiotherapy for symptoms specific to lns. because of the developmental delay seen in babies with lns, these babies may be diagnosed with cerebral palsy. it is very important to create the syndrome-specific physiotherapy program. in order to achieve this, evaluations based on the international classification of functioning, disability and health (icf) model are valuable in terms of showing the right way in the management of the disease.

Eligibility criteria:
inclusion criteria: * having lesch-nyhan syndrome exclusion criteria: -

Keywords: case report lesch-nyhan syndrome genetic disorders
intranasal fentanyl for management of pain associated with cystoscopic procedures

Conditions: Other Acute Pain; Pain Experienced During Cystoscopy

Summary: the purpose of this study is to assess the safety and efficacy of intranasally-administrated fentanyl pectin spray (lazanda®)given to decrease the pain during cystoscopy (the passage of a telescopic instrument into the bladder for purpose of diagnosing the cause of blood in the urine, urinary complaints or any other problems with the urinary bladder). the current standard practice is to use lidocaine jelly (a local anesthetic) given through the urethra to lubricate and decrease local pain. in this study, an additional medicine (lazanda®) is used to reduce pain that occurs during and after the above procedure.

in this prospective study, twenty subjects will be enrolled. the first ten will receive a dose of 100mcg pectin fentanyl nasal spray (lazanda®). the second ten will receive a dose of 200mcg pectin fentanyl nasal spray (lazanda®) if the 100mcg was well tolerated in the first ten. in all cases, lidocaine jelly is used as an local anesthetic in the urethra.

Eligibility criteria:
inclusion criteria: 1. male adult patients scheduled for cystoscopy; additional procedures (e.g. ureteral stent placement, stent exchange, bladder biopsy, retrograde pyelogram) may be included. exclusion criteria: 1. history of analgesic abuse or opioid tolerance 2. allergy to fentanyl or to any of the components of lazanda® 3. acute/chronic nasal problems such as rhinitis or sinusitis 4. acute bronchial asthma / upper airway obstruction 5. presence of bradycardia or history of seizures 6. concomitant use of drugs that inhibit cytochrome p450 isoenzyme 3a4 (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, monoamine oxidase inhibitors and verapamil) or exposure to these drugs 30 days prior to placement on the study. 7. concomitant use of vasoconstrictive nasal decongestants (e.g., oxymetazoline, phenylephrine, xylometazoline) 8. numeric rating scale (nrs) pain score more than 0 at baseline 9. any situation or condition which, in the investigator's opinion, puts the subject at significant risk, or could confound the study results.

Keywords: intranasal fentanyl cystoscopy
deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer; Neoadjuvant Chemoimmunotherapy; Complete Pathological Response

Summary: the purpose of this study is to evaluate the performance of a ct/pet/ wsi-based deep learning signature for predicting complete pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer


Eligibility criteria:
inclusion criteria: 1. age ranging from 20-75 years; 2. patients who underwent curative surgery after neoadjuvant chemoimmunotherapy for nsclc; 3. obtained written informed consent. exclusion criteria: 1. missing image data; 2. pathological n3 disease.
impact of right atrial occlusion on tevar outcomes

Conditions: Thoracic Aortic Aneurysm; Thoracic Aortic Dissection; Thoracic Aorta Abnormality

Summary: though the application of thoracic endovascular aortic repair (tevar) for treatment of aortic pathology is expanding, there remains a gap in the literature examining how intraoperative "reduction or elimination of aortic impulse" (reai) techniques, in particular the use of right atrial occlusion, may impact patient important clinical outcomes. this study aims to provide prospective data from a large cohort of tevar patients to explore clinical outcomes following tevar procedures and, specifically, whether right atrial occlusion has significant impact on clinical outcomes, as compared to other reai techniques. the results from this study may inform future perioperative tevar practices and improve tevar patient outcomes.


Eligibility criteria:
inclusion criteria: * age 18 years or older * thoracic endovascular aortic repair * right atrial balloon occlusion for reduction or elimination of aortic impulse * endograft deployment in landing zones 0-3 exclusion criteria: * age 18 years or younger * non-thoracic endovascular aortic repair * reduction or elimination of aortic impulse using technique other than right atrial balloon occlusion * endograft deployment in landing zones 4 and beyond

Keywords: right atrial balloon occlusion thoracic endovascular aortic repair stent graft repair reduction of elimination of aortic impulse
comparative effects of high and moderate intensity resistance training in young football players

Conditions: Sports Physical Therapy

Summary: football playing is an intermittent sport requiring high intensity dynamic movements, such as acceleration, sprinting and jumping. higher levels of strength and power are crucial for young football players. overuse includes using a muscle too much, too soon before warming up, or too often in gym, tension or stress can cause muscle soreness. doms is thought to be due to temporary muscle damage and inflammation for which the most common trigger appears to be eccentric exercises. exercise induced muscle damage doms is considered a type1 muscle strain injury that has a pain free period of one day. muscle soreness peaks between one to two days. the objective of this study is to compare the effects of high intensity-low volume (hrt) versus moderate intensity-high volume resistance training (mrt) on strength, power and muscle soreness in young football players. study will be a randomized clinical trial, conduct at pakistan football federation lahore through convenient sampling techniques. sample size will be calculated by using g-power. randomization will be done by lottery method. participants will be divided into two groups. group a will receive high intensity resistance training and group b will receive moderate intensity resistance training strength will be calculated by 1rm and sprint test . power will be measured by vertical and horizontal jump. muscle soreness and fatigue will be measured by hooper and mackinnon questionnaire. data will be analyzed by spss version 25

the objective of my study is to compare the effects of high and moderate intensity resistance training on strength, power and muscle soreness in young football players

Eligibility criteria:
inclusion criteria: * male and female players * age 18-24yrs * player with minimum 1-year experience of football * muscle soreness value shouldn't be below normal. * value on hooper and mackinnon questionnaire should be from 1-3. * a minimum score of 3-4 in lower extremity functional scale * fatigue shouldn't regress the normal.(45) exclusion criteria: * history of lower limb musculoskeletal injuries in last 3months * fracture since last 6months * taking drugs or ergogenic supplement * neurological systems are not intact(dermatomes and myotomes) * a minimum score of in lower extremity functional scale.(65, 66)

Keywords: footballer muscle soreness power resistance training sprint
the effects of metabolic & bariatric surgery on lipid metabolism, myeloid-derived suppressor cells, and cancer cell biology

Conditions: Obesity

Summary: this study aims to determine the relationship between lipid kinetics changes and blood immunosuppressive cells by metabolic surgery in two patient cohorts.


Eligibility criteria:
for an eligible subject, all the following must be answered "yes": * biological female sex * age \>=35 and \<=60 years (including pre- and postmenopausal) * self-reported white or black race * the study will enroll approximately 50% white and 50% black subjects * body mass index \>/=40 kg/m2 * have a diagnosis of hyperlipidemia (high triglycerides and ldl-cholesterol) or in treatment with any medication for hyperlipidemia at enrollment * ability to provide written informed consent * allow the collection and storage of biospecimens and data for future use * not having yet started the pre-op liquid diet before the bariatric surgery for an eligible subject, all the following must be answered "no": * have type one or type two diabetes * use of anti-inflammatory medications, such as glucocorticoids or non-steroidal anti-inflammatory medications, within the past 15 days * use of medication approved for obesity management, including, but not limited to, phentermine-topiramate (qsymia), orlistat (xenical), naltrexone-bupropion (contrave), liraglutide (saxenda), and semaglutide (wegovy) * history of cancer of any type * history of chronic conditions known to cause inflammation, such as tuberculosis, autoimmune disease, and human immunodeficiency virus * an acute history (within the past 60 days) or confirmed or suspected sars-cov-2 (covid-19) infection * currently pregnant, breastfeeding, or planning to become pregnant within the next 52 weeks * currently participating in another study with competing outcomes * any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol
sleep and immune checkpoint inhibitors

Conditions: Lung Cancer

Summary: sleep disturbances are prevalent in cancer patients and linked to levels of fatigue and depressive symptoms with a major impact on quality of life. a growing body of evidence links sleep disturbances with various health outcomes, including increased risk of depression, cancer, and overall mortality. inflammation is suggested to be an underlying mechanism both driving and maintaining the symptom cluster of sleep disturbance, fatigue and depressive symptoms, as well as being bi-directionally linked to sleep. the main purpose of the present study is to investigate the prevalence of sleep disturbance and its association with psychological and physical symptoms as well as the clinical response to ici in non-small-cell lung cancer patients (nsclc), with a secondary aim of exploring the role of inflammation.

a total of 240 cancer patients diagnosed with advanced nsclc, referred to treatment with ici will be enrolled in this prospective observational study. patients will be assessed prior to initiation of treatment (baseline) and every third subsequent week, corresponding to each treatment cycle over a period of 18 weeks. assessments will include questionnaires, sleep diaries, actigraphy, and blood and saliva samples to examine sleep, fatigue, psychological and physical symptoms, the sleep-wake-cycle, inflammation, and cortisol. additionally, the patients will be asked to complete a reduced questionnaire every week within the 18 weeks period, to address weekly fluctuations in sleep quality, fatigue, and mood. treatment response is assessed after 9 and 18 weeks. aims: 1. to explore possible associations between sleep and the clinical response to treatment with ici. 2. to investigate the prevalence of sleep disturbance in patients with nsclc during treatment with ici. 3. to prospectively assess changes in sleep parameters over the course of treatment. 4. to examine associations between sleep parameters and fatigue, depression, anxiety, and inflammation. 5. to explore possible associations between sleep, fatigue, depression, inflammatory responses and the clinical response to treatment with icis. hypotheses: patients with high levels of sleep disturbance (insomnia severity) will experience 1) poorer clinical response to ici, 2) more depressive symptoms, 3) higher levels of fatigue, 4) poorer overall health-related quality of life (hrqol), 5) higher levels of inflammation.

Eligibility criteria:
inclusion criteria: - confirmed diagnosis of advanced non-small cell lung cancer exclusion criteria: * insufficient danish proficiency * pre-existing confounding psychiatric illnesses

Keywords: sleep fatigue depressive symptoms immune checkpoint inhibitors lung cancer clinical response
implementation of project yes in ambulatory adolescent & young adult medicine

Conditions: Depression; Eating Disorders; Anxiety

Summary: this study tests a suite of single-session intervention (ssi) targeting risk factors for depression and eating disorders among adolescents and young adults. youth ages 13-25 who screen positive for depression or anxiety as a part of routine care will be offered one of three digital ssis. participants will complete questionnaires before the intervention, immediately after the intervention, and 3-months after completing the intervention so that the study team can investigate if project yes leads to reductions in depression, anxiety and eating disorder symptoms.


Eligibility criteria:
inclusion criteria: * a score \>5 on the phq-9 or a score \>5 on the gad-7 * patient at lurie division of adolescent and young adult medicine * provider agreement that this would be an appropriate intervention * age between 13 and 25 * comfort speaking and reading in either english or spanish exclusion criteria: * inability to speak and understand english or spanish * imminent risk for suicide as indicated by a "yes" response to questions #5 on the ask suicide questions (asq) screener
celebrex total knee arthroplasty study

Conditions: Osteoarthritis; Pain

Summary: this study will investigate the benefits of administering celecoxib (celebrex), a selective cyclooxygenase -2 (cox-2) inhibitor, in treating osteoarthritis (oa) subjects undergoing elective unilateral primary total knee arthroplasty (tka) from the pre-operative phase to the management of post total knee replacement pain, and through the 6 weeks of physical therapy and rehabilitation.


Eligibility criteria:
inclusion criteria: * the subject is a male or female 18 years or older with osteoarthritis of the knee scheduled to undergo elective unilateral primary total knee arthroplasty because of oa, performed under a standardized regimen of anesthesia and procedure. exclusion criteria: * subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis) other than osteoarthritis.

Keywords: perioperative care of total arthroplasty assessing opioid consumption